'Slow-Growth' Global Trend Shakes Up P&G Product Strategy Start To Finish

P&G’s health care segment advanced 4% in the third quarter to $1.84bn, but sales declined for its other business units, a trend the firm sees worldwide across consumer industries. CFO Jon Moeller unveils the firm’s “irresistible superiority” product development strategy to counter slower global consumer spending.

Puzzle

Procter & Gamble Co. counts on “irresistible superiority” in product development, packaging and marketing to spur growth as sales for all but one of its businesses, health care, slumped in its latest quarter.

Its health care unit, marketing products including the Vick’s cough and cold line, Prilosec OTC heartburn medicine, Pepto-Bismol upset stomach formula and the Crest oral care line, recorded sales of $1

P&G’s other categories did not fare as well in the January-March period

More from United States

More from North America